









Markets
/
Stocks
/
nasdaq-avir
/

Atea Pharmaceuticals Inc

AVIR

4.150USD

+0.130+3.23%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

324.23MMarket Cap

LossP/E TTM



Atea Pharmaceuticals Inc

4.150

+0.130+3.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Atea Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Atea Pharmaceuticals Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 52 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Atea Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

52 / 392

Overall Ranking

160 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Atea Pharmaceuticals Inc Highlights

StrengthsRisks

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -2.34, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 54.23M shares, increasing 0.07% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.23M shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.000

Target Price

+49.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Atea Pharmaceuticals Inc is 6.09, ranking 290 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.09

Change



Financials

5.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.39

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.25

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Atea Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Atea Pharmaceuticals Inc is 7.96, ranking 71 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.34, which is -39.65% below the recent high of -1.41 and -64.51% above the recent low of -3.86.

Score

Industry at a Glance

Previous score

7.96

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Atea Pharmaceuticals Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 6.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

6.000

Target Price

+49.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Atea Pharmaceuticals Inc

AVIR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Atea Pharmaceuticals Inc is 9.11, ranking 38 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.55 and the support level at 3.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.89

Change

0.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.031

Buy

RSI(14)

62.882

Neutral

STOCH(KDJ)(9,3,3)

65.333

Neutral

ATR(14)

0.259

High Vlolatility

CCI(14)

54.368

Neutral

Williams %R

18.992

Overbought

TRIX(12,20)

0.812

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

4.084

Buy

MA10

4.051

Buy

MA20

3.810

Buy

MA50

3.489

Buy

MA100

3.291

Buy

MA200

3.290

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Atea Pharmaceuticals Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.18%, representing a quarter-over-quarter decrease of 0.96%. The largest institutional shareholder is The Vanguard, holding a total of 4.23M shares, representing 5.41% of shares outstanding, with 2.06% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BML Capital Management LLC

7.47M

-1.79%

BlackRock Institutional Trust Company, N.A.

6.21M

-2.72%

JPM Partner LLC

5.87M

Fidelity Management & Research Company LLC

5.82M

+1.80%

Tang Capital Management, LLC

4.83M

-1.29%

The Vanguard Group, Inc.

Star Investors

4.71M

-3.64%

Radoff Family Foundation

3.38M

+8.86%

Bain Capital Life Sciences Investors, LLC

2.49M

Geode Capital Management, L.L.C.

1.90M

-1.34%

State Street Investment Management (US)

1.78M

+0.43%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Atea Pharmaceuticals Inc is 4.86, ranking 66 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.23. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.